ZYBERNO
Stock Report
Updated Sep 1, 2026

BioAdaptives Inc. (BDPT)

Healthcare • OTC

$0.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
10.0/100
POOR BUSINESS
BioAdaptives Inc. (BDPT) scores 10/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-3,557.0%)
Return on Capital (Capital Efficiency):CRITICAL (-1,494.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

BioAdaptives Inc. (BDPT) stock report — Zyberno Score 10/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$18.45K

Valuation Multiples (2)

P/S Ratio:0.72x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$269.32K

Price Action & Momentum (1)

% of 52-Week High:2.6%
B. Profitability Assessment

Margin Analysis (3)

Operating Margin Ttm:-3,557.0%
Net Margin Ttm:-4,553.2%
Ebitda Margin:-3,466.2%

TTM Performance (3)

Gross Margin Ttm:77.4%
Operating Margin Ttm:-3,557.0%
Net Margin Ttm:-4,553.2%

Yield Metrics (2)

Earnings Yield:-$9.82K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-100.0%
Latest Earnings Filed:2026-08-19

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):9.3%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.04x
Quick Ratio:0.02x
Cash Ratio:0.01x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-4.10x
Times Interest Earned:-4.10

Capital Structure (4)

Working Capital:-1,777,107.00
Cash And Cash Equivalents:17,909.00
Long Term Debt:$0.00
Net Debt:$250.87K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $25.56K
Linear Growth: 9.3%
📊 Click to view full BDPT Revenue analysis & methodology →
Cost Of Revenue Ttm:$5.77K

Profitability Breakdown (2)

Gross profit TTM: $19.79K
Linear Growth: 25.3%
📊 Click to view full BDPT Gross Profit analysis & methodology →
-$909.20K

Bottom Line Performance (3)

-$1.16M
Income Before Tax:-$498.41K
Ebitda Ttm:-885,995.00

Operating Expenses (5)

Operating Expenses:928,987.00
R And D Expense:0.00
Sga Expense:838,028.00
Income Tax Expense:$0.00
Interest Expense:254,379.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:16,800.9%
Ebitda Margin:-3,466.2%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$78.77K
Current Assets:$67.77K
Ppe Net:11,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:1,844,874.00
Current Liabilities:1,844,874.00
Long Term Debt:$0.00
Short Term Debt:$268.77K

Equity & Capital (3)

Equity:-$1.77M
Retained Earnings:-$10.68M
Common Stock:1,250,000,000.00

Working Capital Items (3)

Accounts Receivable:59.00
Inventory:36,046.00
Accounts Payable:268,774.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:28,670.00
C. Cash Flow Analysis

Operating Activities (2)

-$502.96K-$534.03K

Investment Activities (1)

Investing Cash Flow:-$18.00K

Financing Activities (3)

Financing Cash Flow:$0.00
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:178,100.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:23,205.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (2)

-$0.16
Earnings Per Share Ttm:-$0.08

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.00
Operating Cash Flow Per Share:-$0.04

Book Value & Capital (2)

Book Value Per Share:-$0.12
Cash Per Share:0.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.18x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:433.24x
Days Sales Outstanding Ttm:0.84

Inventory Management (2)

Inventory Turnover Ttm:0.16x
Days Inventory Outstanding Ttm:2,278.63

Payables & Cash Cycle (2)

Days Payable Outstanding:16,990.39
Cash Conversion Cycle:-14,710.92
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):9.3%

Other Growth Rates (1)

Gross Profit Growth Rate (Linear):25.3%
C. Company Profile & Context

Corporate Information (6)

Symbol:BDPT
Company Name:BioAdaptives Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:14.19M
Shares Outstanding Basic:14.19M
Shares Outstanding Diluted:281.20M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 23:46:27 UTC
Data Timestamp:2026-08-22T21:29:25.355550
Scroll to Top